Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2026-05-13 Interim / Quarterly Rep…
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
10-Q - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-13 English
8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the U.S. SEC, covering multiple regulatory items (entry into a credit agreement, results of operations, FD disclosure, exhibits). It is a general compliance/regulatory filing rather than a standalone earnings release or investor presentation. Hence it falls under the Regulatory Filings (RNS) category.
2026-05-13 English
8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
Regulatory Filings Classification · 85% confidence The document is a Form 8-K “Current Report” filed under the Securities Exchange Act, specifically an Item 7.01 Regulation FD Disclosure furnishing a press release. It does not present full financial statements or quarterly results, nor does it fall under any specialized category like earnings release, M&A, or AGM materials. It is a routine SEC regulatory filing and thus best fits the fallback category “Regulatory Filings” (RNS).
2026-05-07 English
ARS - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
Annual Report
2026-04-27 English
8-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 27, 2026, reporting the appointment of a new board member, Dr. Daniel Gilmer. The key section is Item 5.02, which specifically addresses the departure and appointment of directors or principal officers. The content focuses on management changes, including compensation arrangements and indemnity agreements related to the new director. There are no financial statements or detailed financial data presented, and the document is not an earnings release, annual report, or other financial report. The primary purpose is to announce changes in the company's board of directors. Therefore, the document fits the category of Board/Management Information (MANG). The document length (6156 characters) supports that it is a substantive filing rather than a brief announcement or certification. Hence, the classification is MANG with high confidence.
2026-04-27 English
10-K - Armata Pharmaceuticals, Inc. (0000921114) (Filer)
Annual Report FY 2025
2026-03-25 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.